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Abstract 
Background:  Depression, chronic pain and opioid dependence are conditions commonly 
encountered in primary care settings.  These comorbidities create treatment challenges while 
negatively influencing outcomes of care. The Patient Health Questionnaire (PHQ9) and Global 
Pain Scale (GPS) are valid screening tools used to score depression and pain symptoms. The 
purpose of this study was to determine the relationship between the PHQ9 and Global Pain Scale 
(GPS) scores in opioid dependent adults with chronic pain to determine whether both tools are 
necessary.  
 
Methods: This was a descriptive study using a retrospective correlational research design. Data 
was obtained from the electronic medical records (EMR) of 44 patients enrolled in a Chronic 
Opioid Analgesic Therapy (COAT) clinic between August 1, 2016 and July 31, 2017. Privacy 
was maintained through de-identification of data.  The variables were analyzed using SPSS 
statistical software after all data was collected.  
 
Results: A significant and positive correlation exists between the PHQ9 and GPS total scores (r 
= .63). In addition, all the sub scores of the Your Activities and Your Clinical Outcomes of the 
GPS were statistically significant and positively correlated to the PHQ9 at p = <0.05. 
 
Conclusion: Understanding the relationship between the PHQ9 and GPS scores in adults with 
chronic pain and opioid dependence can improve depression screening and reduce respondent 
fatigue. The results of this study indicate the GPS may be sufficient to screen for depression, and 
the PHQ9 could be eliminated from the screening process.  
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Evaluating the Relationship Between PHQ9 and Global Pain Scale (GPS) Scores in Opioid 
Dependent Adults at the Polk Dalton Clinic 
Introduction 
 Patients with chronic pain, depression and substance use disorders (SUD) are routinely 
treated in primary care. Approximately 52% of primary care patients are diagnosed with chronic 
pain (>3months), 5-13% have depression and 19% have a SUD (Barrett & Chang, 2016). These 
health issues are multidimensional and complicated by the fact that 50% of patients with 
depression and 65% with substance use disorders are undiagnosed or do not seek help (Barrett & 
Chang, 2016).  The overlapping of depression, chronic pain and substance use, such as opioid 
dependence, presents treatment challenges to healthcare providers.  
 The US Preventive Services Task Force (USPSTF) recommends screening for depression 
in the adult population (age 18 or older) regardless of risk factors (Siu, 2016). This Grade B 
recommendation states depression screening should be performed with systems in place to 
provide “accurate diagnosis, effective treatment, and appropriate follow-up” (Siu, 2016, pg. 
382). In this study, opioid dependent adults with chronic pain at a primary care clinic were 
screened for depression and pain symptoms using the Patient Health Questionnaire (PHQ9) and 
the Global Pain Scale (GPS) tools at each visit. The purpose of this DNP project is to determine 
the relationship between the PHQ9 and GPS scores in order to improve screening efficiency by 
eliminating unnecessary screening tools and decreasing survey response fatigue.     
Background 
 Depression affects 350 million people worldwide, and fewer than half of all those who 
are diagnosed with depression receive treatment (WHO, 2016). The extensive influence 
depression has on medical conditions, behaviors and outcomes of care can make treatment 
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challenging. Also, there is a strong association between physical and mental health (WHO, 
2016). Depression has been shown to contribute to negative health behaviors in adults, such as 
obesity and smoking, and it is associated with many chronic diseases and conditions including 
diabetes, hypertension, stroke, heart disease, and cancer (CDC, 2016). The presence of 
depression and a co-existing health condition can affect functioning, quality of life, utilization of 
health care services, and health care costs (Barrett & Chang, 2016).  
  Chronic pain affects 100 million Americans, and is associated with poor social 
relationships, isolation, financial problems, and depression (Barrett & Chang, 2016). In addition, 
Barrett & Chang (2016) report the prevalence of substance use disorders (SUD) in patients with 
chronic pain is estimated at 48%.  The authors state a diagnosis of depression along with chronic 
pain can increase pain intensity, disability, and negatively influence the clinical outcomes of pain 
treatment.  The association between chronic pain, depression and substance use can interfere 
with effective depression diagnosis, treatment and outcomes of care (Barrett & Chang, 2016). 
The National Institutes of Health (NIH) recommends utilizing behavioral health interventions in 
primary care settings where the comorbidities of opioid dependence, chronic pain and depression 
are present (Barrett & Chang, 2016).  
  Primary care providers may prescribe opioids to manage chronic pain with three to four 
percent of adults on long-term opioid therapy in the United States (Dowell, Haegerich, & Chou, 
2016).   More than 650,000 opioid prescriptions are written each day (HHS, 2016). The ethical 
and safety issues surrounding the prescribing of opioids for chronic pain include complications 
related to abuse and overdose (Dowell et al, 2016). Primary care providers must adopt measures 
to safely prescribe opioids for chronic pain without contributing to the growing problem of 
opioid dependence, abuse and related deaths from opioid misuse. An estimated 1.9 million 
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people were dependent on or abused prescription opioid medications in 2013 (Dowell et al., 
2016), and prescription opioids were to blame for nearly half of all opioid overdose deaths in 
2016 (CDC, 2018).  
  Opioids are effective and safe for the treatment of chronic pain in patients who are 
candidates for long-term use. Ballantyne (2015) states low doses of opioids can decrease pain 
and improve function in elderly patients with arthritis who cannot tolerate alternative treatments. 
The author also reports patients with serious disease states who have not restored function with 
other forms of treatment can also benefit from opioids. Suitable candidates must be screened and 
selected based on risk assessment and a complete history and physical to ensure safe treatment 
(Ballantyne, 2015). The decision to treat with chronic opioid therapy should be based on the 
benefits versus risk along with implementing written agreements and routine monitoring to help 
prevent misuse and abuse of opioids (Ballantyne, 2015).  
 The onsite Chronic Opioid Analgesic Therapy (COAT) clinic at an urban primary care 
medical office safely provides opioid treatment for patients with a chronic pain diagnosis. 
Acceptance into the COAT clinic is determined on an individual basis. The patients are required 
by contract to visit the clinic once a month where they are screened for depression and pain 
along with receiving a monthly prescription for opioids. It is important to screen this patient 
population for depression as many individuals with chronic pain often have depressive symptoms 
(Boakye et al., 2016).  
 Furthermore, depression increases pain intensity and often accompanies opioid use in 
adults with chronic pain (Barrett & Chang, 2016). Opioid dependent adults diagnosed with 
chronic pain and depression benefit from collaborative health treatments provided by a team of 
medical and nursing professionals, along with psychological and social work interventions 
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(Barrett & Chang, 2016).  A barrier to effective treatment of depression is inaccurate assessment 
and diagnosis (WHO, 2016). Hence, it is important to effectively screen and accurately diagnose 
depression in opioid dependent adults.  
 Screening tools can play a significant role in identifying those individuals at risk for 
depression. The Patient Health Questionnaire (PHQ9) is used to screen COAT clinic patients for 
depression symptoms at each monthly visit. It is a tool approved by the USPSTF for depression 
screening in adults (Siu, 2016). The PHQ9 can screen, diagnose, monitor and measure the 
severity of depression over time by rating the frequency of symptoms. Positive PHQ9 screenings 
should be followed up with additional assessments of depression severity and other 
psychological problems, such as anxiety (Siu, 2016).   
 The Global Pain Scale (GPS) is also administered at each COAT clinic visit to screen for 
pain, functioning and emotional well-being. This screening tool gives information on how 
chronic pain affects daily life.  The evaluation of the correlation between the PHQ9 and GPS can 
improve the screening process in opioid dependent adults who suffer from chronic pain and 
depression. The use of only one of these tools may be all that is necessary to accurately screen 
for symptoms of depression.  
Theoretical Framework 
 For this study, certain determinants of the theory of planned behavior can be used to 
understand individual habits and behaviors related to screening. Aizen, 1991 states the three 
determinants of this theory are attitude toward the behavior, subjective norms, and perceived 
behavior control. The author defines attitude toward the behavior as the extent to which the 
patient believes the behavior is beneficial or not, and the subjective norm as the social pressure 
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felt to perform the behavior. The third determinant is perceived behavior control, which is 
whether the individual feels the behavior will be easy or difficult to perform (Ajzen, 1991).  
 All three determinants interact to influence and predict intentions to engage in certain 
behaviors. Shah, Scogin, Pierpaoli, and Shah (2018) found both attitudes and subjective norms 
were strong predictors of willingness to complete depression screenings. The authors found most 
adults were receptive and felt there was a benefit to depression screening. Increasing subjective 
norms through education was also a strong predictor of screening acceptance (Shah et al. (2018). 
Perceived behavior control has not been shown to affect screening behaviors in a study 
completed by Breau, (2014).  
Purpose 
  The monthly screening of COAT clinic patients with two screening tools at each visit 
raises the issue of poor response reliability due to survey respondent fatigue. Appropriate time 
intervals for screenings are not known (Siu, 2016); however, monthly screening with two tools 
could be burdensome for patients.  The purpose of this project is to evaluate and compare the 
screening scores of the PHQ9 and the GPS in opioid dependent adults with chronic pain. The 
purposeful examination of these screening tools may eliminate overlap and repetition of 
depression screening to prevent survey fatigue.  
The primary objectives are: 
1. Describe the patient population in the Chronic Opioid Analgesic Therapy (COAT) clinic 
patients in terms of demographics (gender, age, ethnicity), depressive symptoms, and 
pain scores (GPS, Current Pain Level (CPL) and Acceptable Pain Level (APL)) 
2. Examine the relationship between depressive symptoms (using PHQ9) and pain scores 
(using the GPS) in the COAT Clinic patients 
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3. Determine the relationship between demographics (gender, age, ethnicity) and depressive 
symptoms (using the PHQ9) and pain scores (using the GPS) in the COAT Clinic 
patients.  
4.   Determine if acceptable pain level (scale ranging 0-10) correlates to depressive 
 symptoms (using PHQ9) in the COAT clinic patients.  
5.   Determine the correlation between pain level (scale ranging 0-10) and depressive 
 symptoms (using PHQ9) with the clinical outcomes and activities (using the GPS) in the 
 COAT clinic patients. 
Methods 
Study Design 
 This study utilized a correlational study design to determine the relationship between the 
PHQ9 and GPS scores in the COAT clinic patients. A correlation analysis describes the strength 
and direction of the linear relationship between two variables (Pallant, 2016). A retrospective 
review of electronic medical records provided the data used in the analysis.  
Sample Selection and Site 
 A primary care medical office in an urban setting was the site for this study. This primary 
care clinic offers family medical services across the life span. The sample for this study was 
obtained by extracting de-identified data from the electronic medical record (EMR) of Chronic 
Opioid Analgesic Therapy (COAT) clinic patients. All adult COAT clinic patients seen between 
August 1, 2016 and July 31, 2017 were included in the sample. Patients who did not complete 
the PHQ9 or GPS were excluded from the study. The sample size was 44 patients.  
 
 
EVALUATING THE RELATIONSHIP BETWEEN PHQ9 AND GLOBAL     
 8	  
Measures 
 The PHQ9 has 9 questions in a self-report tool incorporating DSM-IV depression 
diagnostic criteria.  The frequency of symptoms are scored with a score of 5-9= minimal 
symptoms, 10-14= minor depression, dysthymia, mild depression, 15-19= major depression, 
moderately severe, >20= major depression, severe (CDC, 2016). The PHQ9 screening scores of 
10 or higher have a sensitivity of 88% and a specificity of 88% for major depressive disorder 
(Savoy & O’Gurek, 2016).   
 The Global Pain Scale (GPS) assesses the physical and psychological impact of chronic 
pain on the individual. It is a simple and easy method to measure and track pain and treatment 
outcomes. This screening tool utilizes an eleven-point Likert scale (0-10) with 4 subscales: your 
pain, your feelings, your clinical outcomes, and your activities (Gentile, Woodhouse, Lynch, 
Maier and McJunkin, 2011).  The ‘Your Pain’ subscale asks about current pain, along with the 
best, worst and average pain over the past week. The ‘Your Feelings’ subscale asks participants 
how they have felt in the past week related to the emotions of being afraid, depressed, tired, 
anxious and stressed. The ‘Your Clinical Outcomes’ subscale questions are related to the effect 
of chronic pain on sleeping, feeling comfortable, personal independence, working or performing 
normal tasks and medication use during the past week.  The fourth subscale is ‘Your Activities’, 
and it asks whether the individual was able to go to the store, do chores in the home, enjoy 
friends and family, exercise and participate in hobbies during the past week.  
 Each GPS subscale is worth 25 points with a maximum total score of 100. The score is 
achieved by adding up the total score and then dividing by two. Higher scores represent 
worsened conditions.  Gentile et al. (2011) found the total GPS scale reliable (Cronbach alpha 
0.89) along with each subscale (pain 0.87,feelings 0.84, clinical outcomes 0.72, and activities 
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0.96). This screening tool has significant and moderate inter-correlations between subscales, 
which indicates high construct and criterion validity (Gentile et al, 2011). Therefore, the GPS 
and its subscales provide a good option for a reliable and valid method to screen for pain and 
depressive symptoms. 
 Acceptable Pain Level (APL) was recorded as the level of pain that is acceptable to the 
patient.  It was measured with a scale of 0-10.  The Current Pain Level (CPL) was the subjective 
level of pain at the time of the visit measured using a scale of 0-10.  For both of these measures, 
a score of zero would be “no pain”, and a score of ten would be “the worst possible pain”.  
 Demographic variables were also collected to describe the sample. They included gender, 
age and ethnicity.  
Procedures  
 Data collection for this study did not involve direct contact or intervention with the 
subjects, so informed consent was not necessary. The principal investigator was the sole 
researcher, and all EMR data extraction was performed on a desktop computer at the primary 
care clinic under the direct supervision of the COAT clinic director. Data extraction occurred 
from November 2017 to April of 2018. The patient visit within this time frame that included both 
PHQ9 and GPS scores was the dated used to extract study variables. Data was extracted and 
placed in an Excel spreadsheet. The spreadsheet and all relevant study variables were stored on 
an encrypted USB drive. The data was de-identified, and the confidentiality of the subject’s 
personal health information (PHI) was maintained. Human subjects exempt approval was 
obtained from the University of Kentucky Office of Research Integrity.   
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Statistical Analysis 
 Data was analyzed using SPSS software. The variables were summarized using 
descriptive statistics. The association or relationship between variables was tested with Pearson 
product moment correlation, Spearman’s rho, and two sample t-tests (Levene’s Test for Equality 
of Variances).  Equal variances were assumed for the t-tests. Significance level was set at 0.05. 
Statistical analysis occurred at the completion of data collection.  
Results 
Demographics 
 The patient population was described using demographics, depressive symptoms, and 
pain scores (Objective 1). Forty-four charts were reviewed and demographic variables included 
gender, age and ethnicity. Females accounted for 77% (n=34) of the sample.  Those between the 
ages of 56-65 years old represented 43.2% of the sample. The sample was evenly divided 
between Caucasians and African Americans. 
 The continuous variables of PHQ9, GPS, APL, and CPL were summarized using 
frequencies along with the mean and standard deviation. The majority of COAT clinic patients 
(68%) reported minimal to mild symptoms of depression on the PHQ9.  Eight patients (18.2%) 
had moderate depressive symptoms and six individuals (13.6%) reported moderate to severe 
symptoms.  There were no severe depression screening scores 
 The descriptive analysis of pain scores resulted in a GPS total score mean of 31(18.31). 
The current pain level mean was 6.23 (2.19), and the APL mean was 5.05 (1.18). In addition, the 
means were calculated for the ‘Your Clinical Outcomes’ and ‘Your Activities’ individual 
subscales. See Table 1.  
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Relationship between PHQ9, Acceptable Pain Level and GPS 
  The results for objective two indicate a significant and positive correlation between the 
overall PHQ9 and the overall GPS scores at 0.000 (r = .63). The relationship between the 
Acceptable Pain Level (APL) and PHQ9 (p = .08) was not statistically significant in this sample 
(Objective 4). See Table 2.  
              Table 2. Correlations among PHQ9, Acceptable Pain Level, and GPS  
 PHQ9 
 
r (p) 
Acceptable Pain Level (APL) .27 (.08) 
Global pain score (GPS) .63(< .001)** 
                     ** p = 0.01  
 
 
Relationship between Demographics and PHQ9 and GPS 
 The relationship between the sample demographics, PHQ9 and GPS (Objective 3) was 
evaluated using group means, standard deviations, Spearman’s rho and independent samples t-
tests.  The results were not statistically significant (Table 3.). The p value at >.05 and the small 
rho value indicate a weak correlation between the demographics of age, gender and ethnicity and 
the PHQ9 and GPS scores.  
Relationship between Current Pain Level, PHQ9 and Activities and Clinical Outcomes 
Subscales of the GPS scales  
 Correlational analysis for Objective 5 illustrated positive and significant correlations 
between CPL and the ‘Your Activities’ sub score specifically the item of enjoying friends and 
family (r= .41, p =.01).  The current pain level also had positive and significant relationships 
with the ‘Your Clinical Outcomes’ sub scores related to difficulty sleeping (r =.34, p =.03), 
comfort (r=.36,  p =.02), and need for medication (r=.35, p =.02) See Table 4. In addition, all of 
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the sub scores of the ‘Your Activities’ and ‘Your Clinical Outcomes’ were statistically 
significant and positively correlated to the PHQ9 (p = < .05). See Table 5.  
Discussion 
Key Findings  
 In this study, the demographic, depressive and pain scores were described for the patients 
in the COAT clinic. Relationships were explored between the demographics and PHQ9 and GPS 
scores. Significant correlations were found between the PHQ9 and GPS total scores. In addition, 
the GPS subscales of  ‘Your Clinical Outcomes’ and ‘Your Activities” were positively correlated 
with the PHQ9 and Current Pain Levels.  
 The sample was primarily women, middle aged and equally distributed between African 
Americans and Caucasians.  These findings are relevant since the prevalence of major depression 
is higher in women than in men (Albert, 2015), and chronic pain has been shown to increase 
symptoms of depression (Barrett & Chang, 2016). The majority of reported depressive symptoms 
were minimal to mild. This may be due to survey respondent fatigue or antidepressant therapy.  
Data was not collected to determine those currently treated with either psychotherapy or 
pharmacotherapy for depressive symptoms; however, it is well known the use of antidepressant 
medications and psychotherapy are effective in reducing depressive symptoms (Cuijpers, 
Sijbrandij, Koole, Andersson, Beekman, and Reynolds, 2013).  
 The total GPS, APL and Current Pain Level scores were moderate. This could be due to 
some level of pain control by the prescribed opioid medication. Opioids in low doses can be 
helpful to decrease pain in low-risk individuals with a chronic pain diagnosis (Ballantyne, 2015).  
Pain management along with depression screening is important for the COAT clinic patients. 
Depression and pain are inter-related, and chronic pain can increase symptoms of depression.   
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 The relationship between pain and depression was evaluated in Objectives 2 and 4 using 
the PHQ9, APL and total GPS scores. The close relationship between the PHQ9 and GPS 
indicates these two screening tools may be testing the same concepts. In particular, many of the 
questions in the GPS are related to emotions and function, which are similar to the PHQ9. The 
finding reinforces the close relationship between chronic pain and depression (Burke, Mathias, 
and Denson, 2015), and this relationship is present in the research. According to Barrett & Chang 
(2016), there is an intricate overlapping of chronic pain and depression pathways in the brain, 
and depression can create sensory changes that result in increased pain sensitivity. In contrast to 
the GPS, the APL scores do not show a relationship to the PHQ9. No evidence to support a 
relationship between APL and depression was found in the literature, but since APL is a 
subjective report of an acceptable pain level there may actually be a connection even though this 
study does not support it.  
 The PHQ9 and GPS have no preference or relationship to gender, age or race in this 
study (Objective 3). These results do not match literature findings on this topic.  Research 
suggests older adults and African Americans are at an increased risk for experiencing depression 
(CDC, 2018).  In addition, the Centers for Disease Control and Prevention (2018) report women 
are almost twice as likely to have depressive symptoms than men. The lack of connection 
between the PHQ9 and GPS for gender, age and race might be attributed to the adequate control 
of pain and depression resulting in lower screening scores. Unreliable screening results due to 
response burden and survey fatigue may have affected results as well.   
 Results suggest depressive symptoms and reported pain level have an effect on daily 
activities and functioning (Objective 5). Duenas, Ojeda, Salazar, Mico and Failde (2016) report 
chronic pain can have a negative impact on quality of life and daily activities.  In particular, the 
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authors state there is a strong correlation between chronic pain and decreased physical activity, 
such as walking, performing chores around the house and participating in social activities. A 
chronic pain diagnosis can cause sleep disturbances, work absenteeism, increased stress levels 
and poor mental health (Duenas et al. 2016). Like chronic pain, symptoms of depression were 
found to negatively affect quality of life, increase stress and interfere with physical, interpersonal 
and social activities (Jayasekara et al. 2015).  All ten items of the GPS subscales ‘Your Clinical 
Outcomes’ and ‘ Your Activities” correlated with the PHQ9. Interestingly, these ten times are 
also symptoms of depression.   
Implications for Practice 
 There is a significant and positive correlation between the PHQ9 and GPS; therefore, an 
implication for future practice could be to remove the PHQ9 and only screen with the GPS. This 
would prevent test redundancy and problems with over screening. Excessive screening can lead 
to inappropriate treatment and may not always improve outcomes (Lenzer, 2017).  The benefit 
versus harm of depression screening should take into consideration the difference between 
treating patients who have clinical depression compared to those who only screen positive 
(Lenzer, 2017).   
 On the other hand, there may be a detriment to patient care if a pain scale is used 
exclusively without a depression scale. Providers may only diagnose and treat pain whereas 
unidentified depression might be undertreated.  Although the USPSTF does not recommend an 
ideal screening interval, clinical judgment should be used to determine if more frequent 
screenings with the PHQ9 are necessary depending on assessment of individual patient risk 
factors (Siu, 2016).  
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 Further implications for practice could include the addition of an on site psychiatric 
APRN who can further evaluate and treat those patients who screen positive for depression. Over 
60% of the COAT clinic patients had mild to moderate-severe depressive symptoms. The 
assumption is that a decrease in depression symptoms will result in a decrease in pain symptoms 
and lower opioid dependence. In addition, diagnosis and treatment of depression can improve 
symptoms and quality of life (Barrett & Chang, 2016). 
Implications for Future Study 
 Implications for future study include performing statistical analysis to determine the 
relationship between the ‘Your Feelings’ subscale of the GPS and the PHQ9.  The ‘Your 
Feelings’ subscale measures how pain is affecting the emotional state of the patient (afraid, 
depressed, tired, anxious, and stressed) over the past week.  This was not addressed in this study, 
but it may affect the strength of the correlation between the overall PHQ9 and GPS scores. A 
factor analysis between the PHQ9 and GPS scores should also be done to determine PHQ9 and 
GPS similarities. Furthermore, data extraction from the EMR about antidepressant use could be 
relevant to the screening scores and frequency distribution. The PHQ9 score of those already 
being treated with antidepressant therapy may reflect different results than those who are 
untreated.  
  Identifying the relationship between the individual’s dose of opioid pain medication and 
the PHQ9 and GPS screening scores would also be of interest. It is well known chronic use of 
opioids is associated with depression, and those patients with depression are nearly twice as 
likely to use opioids for long-term pain relief (Davis, Lin, Liu and Sites, 2017).  Increased opioid 
use in individuals with symptoms of depression can help identify the potential for adverse opioid 
treatment outcomes, such as misuse and overdose. (Davis et al. (2017)..  
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Limitations 
 There were several limitations identified with this study.  For example, this study has a 
small sample size (N=44) and was conducted in one clinical setting. Therefore, the results may 
not be transferable or generalized to a larger population or setting.  Also, the PHQ9 and GPS are 
validated screening tools, but repeated screening exposures may lead to desensitization resulting 
in unreliable scores. Furthermore, these screening tools are self-reported and subjective which 
increases the risk of response bias. Finally, there were at least three separate health care 
providers documenting screening scores in the EMR, which may have resulted in inconsistent 
data entry errors.   
Conclusion 
Patients with chronic pain, depression and opioid dependence present clinical treatment 
challenges in primary care. The PHQ9 and the GPS are reliable tools used to regularly screen for 
depression and chronic pain symptoms in this patient population. The administration of two 
screening tools at the monthly COAT clinic visit may not be necessary and can lead to excessive 
screening and inappropriate treatment. The results of this study show the GPS alone may be 
sufficient to screen for depression. Eliminating or decreasing screening frequency with the 
redundant PHQ9 could help lower survey respondent fatigue and improve response reliability 
and screening effectiveness in opioid dependent adults with chronic pain. This practice change 
may also enhance chronic pain management.  
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Table 1. Characteristics of Sample (N=44) 
N= 44 Mean (SD) or n (%) 
Gender 
Female 
Male 
 
34 (77.3%) 
10 (22.7%) 
Age 
26-35 
36-45 
46-55 
56-65 
66-75 
76-85 
86+ 
 
0 (0.0%) 
5 (11.4%) 
5 (11.4%) 
19 (43.2%) 
13 (29.5%) 
2 (4.5%) 
0 (0.0%) 
Ethnicity 
Caucasian 
African Am 
Other 
 
22 (50.0%) 
22 (50.0%) 
0 (0.0%) 
PHQ9 
Total 
Minimal 0-4 
Mild 5-9 
Mod 10-14 
Mod-Sev 10-14 
Severe >14 
 
3.57 (4.11) 
15 (34.1%) 
15 (34.1%) 
8 (18.2%) 
6 (13.6%) 
0 (0.0%) 
Total GPS 
 
Clinical Outcomes 
 During the Past week: 
I had trouble sleeping 
I had trouble feeling comfortable 
I was less independent 
I was unable to work (do normal tasks) 
I needed to take more medication 
Activities 
During the past week I was NOT able to: 
Go to the store 
Do chores in my home 
Enjoy my friends and family 
Exercise (including walking) 
Participate in my favorite activities 
31.00 (18.31) 
 
 
 
2.12 (2.85) 
2.65 (3.24) 
2.28 (3.25) 
2.67 (3.79) 
1.86 (3.31) 
 
 
2.37 (3.24) 
2.70 (3.43) 
2.00 (2.96) 
3.14 (3.73) 
2.53 (3.57 
Current Pain Level 6.23 (2.19) 
Acceptable Pain Level 5.05 (1.18) 
 
 
 
EVALUATING THE RELATIONSHIP BETWEEN PHQ9 AND GLOBAL     
 18	  
 
 
Table 3.  Correlations among demographics, PHQ9 and GPS 
Demographic 
characteristics 
PHQ 9 Global Pain Scale 
test statistic p test statistic P 
 
Age 
 
 
 
 
rho= -.18 
 
.24 
 
rho= -.13 
 
.39 
 Mean (SD) p Mean (SD) P 
Gender 
   Female 
   Male 
 
3.56 (4.05) 
3.60 (4.53) 
 
.691 
 
31.88 (18.11) 
27.98 (19.68) 
 
.750 
Ethnicity 
   White 
   African Amer 
 
1.41 (4.34) 
3.73 (3.95) 
.524  
26.63 (16.98) 
35.36 (18.93) 
.422 
 
 
 
 
Table 4.  Correlations among Current Pain Level, Activities and Clinical Outcomes 
 Current Pain level 
 r(p) 
Your Activities  
Go to the store .17(.29) 
Do chores in my home .15(.33) 
Enjoy my friends and family .41(.01)** 
Exercise (including walking) .23(.14) 
Participate in my favorite hobbies .25(.11) 
Your Clinical outcomes  
I had trouble sleeping .34(.03)* 
I had trouble feeling comfortable .36(.02)* 
I was less independent .16(.30) 
I was unable to work (or perform normal tasks) .07(.70) 
I needed to take more medication .35(.02)* 
** p = 0.01 level  
*   p = 0.05 level  
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Table 5. Correlations among PHQ9, Clinical Outcomes and Activities 
 PHQ9 
 r(p) 
Your Activities  
Go to the store .53(.00)** 
Do chores in my home .35(.02)* 
Enjoy my friends and family .55(.00)** 
Exercise (including walking) .47(.00)** 
Participate in my favorite hobbies .56(.00)** 
Your Clinical outcomes  
I had trouble sleeping .53(.00)** 
I had trouble feeling comfortable .64(.00)** 
I was less independent .60(.00)** 
I was unable to work (or perform normal tasks) .48(.00)** 
I needed to take more medication  .34(.03)* 
** p = 0.01 level  
*  p = 0.05 level  
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Image 1. Patient Health Questionnaire (PHQ9) 
 
 
 
 
 
 
 
 
P A T I E N T  H E A L T H  Q U E S T I O N N A I R E - 9   
( P H Q - 9 )  
Over the last 2 weeks, how often have you been bothered 
by any of the following problems? 
(Use “✔” to indicate your answer) Not at all 
Several 
days 
More 
than half 
the days 
Nearly 
every 
day 
1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3. Trouble falling or staying asleep, or sleeping too much 0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down 0 1 2 3 
7. Trouble concentrating on things, such as reading the 
newspaper or watching television 0 1 2 3 
8. Moving or speaking so slowly that other people could have 
noticed?  Or the opposite — being so fidgety or restless 
that you have been moving around a lot more than usual 
0 1 2 3 
9. Thoughts that you would be better off dead or of hurting 
yourself in some way 0 1 2 3 
                                                                                                              FOR OFFICE CODING     0      + ______  +  ______  +  ______ 
=Total Score:  ______ 
 
     
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
Not difficult  
at all 
 
Somewhat  
difficult 
 
Very  
difficult 
 
Extremely  
difficult 
 
 
 
 
 
 
 
 
 
 
Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from 
Pfizer Inc.  No permission required to reproduce, translate, display or distribute. 
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Image 2: Global Pain Scale (GPS) 
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